Abound Wealth Management’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$282 Hold
2
– – ﹤0.01% 1109
2026
Q2
$246 Hold
2
– – ﹤0.01% 1072
2026
Q1
$211 Sell
2
-2
-50% -$177 ﹤0.01% 1224
2025
Q4
$350 Hold
4
– – ﹤0.01% 1008
2025
Q3
$266 Hold
4
– – ﹤0.01% 1039
2025
Q2
$222 Hold
4
– – ﹤0.01% 1003
2025
Q1
$194 Hold
4
– – ﹤0.01% 995
2024
Q4
$155 Sell
4
-1
-20% -$44 ﹤0.01% 1165
2024
Q3
$225 Buy
+5
New +$202 ﹤0.01% 1094

Other funds holding PTGX

Abound Wealth Management's PTGX Position: Q3 2026 in Review

Abound Wealth Management held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 2 shares worth $282. The position accounts for ﹤0.01% of the portfolio, ranked #1109.

Abound Wealth Management first reported a position in PTGX in Q3 2024 and has held it in 9 quarters since. The position peaked at $350 in Q4 2025. 380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Abound Wealth Management held 2 shares of Protagonist Therapeutics worth $282 as of Q3 2026.
  • Abound Wealth Management left its Protagonist Therapeutics share count unchanged in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Abound Wealth Management's portfolio in Q3 2026, its #1109 holding.
  • Abound Wealth Management first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • Abound Wealth Management's Protagonist Therapeutics position peaked at $350 in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Abound Wealth Management's 13F filing for Q3 2026, filed 26 Oct 2026.